News

(RTTNews) - Novartis (NVS) announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria or CSU.

In the pivotal Phase III studies, REMIX-1 and REMIX-2, remibrutinib treatment showed significant symptom improvement early, which was sustained up to Week 52, in patients with CSU who remained symptomatic despite second-generation H1-antihistamine use.

The company noted that Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52) .

The company said Remibrutinib demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo.

Novartis plans to submit remibrutinib for approval in chronic spontaneous urticaria (CSU) to global health authorities starting in the second-half of 2024, and continues to investigate remibrutinib in multiple immune-mediated conditions.

Data reaffirmed the first-in-class potential of remibrutinib for the more than 50% of patients with CSU uncontrolled by H1-antihistamines who continue to live with painful and debilitating symptoms.

For More Such Health News, visit rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.